Emelia Hunt advises on a wide range of corporate transactions, including private mergers and acquisitions (both domestic and cross-border), public takeovers, IPOs, fundraisings, joint ventures, restructurings and private equity-back transactions, as well as corporate advisory work. Emelia has also been involved in a number of life sciences transactions, including the global distribution of the covid-19 vaccine for two major pharmaceutical companies.

Emelia represents clients across a broad range of sectors, including financial services, real estate, and insurance, but has a particular interest in and focus on healthcare, life sciences and technology.

Emelia is also active in pro bono work at the firm. In 2021 she successfully represented a pro bono client in a building dispute in court and is currently assisting a family with their immigration applications.


  • Omega Healthcare Investors, Inc., in a number of transactions concerning its acquisition and lease of UK healthcare facilities and general corporate advisory work.
  • Touchlight Genetics on renegotiated license with AskBio and joint venture exit.
  • Wheels Up Experience, Inc. on its recommended all-cash acquisition by way of a scheme of arrangement of Air Partner plc, a publicly listed company on the London Stock Exchange.
  • Touchlight, on various corporate matters, including fundraising from private equity.
  • Mark G. Anderson Consultants Inc., on its acquisition of London-based property and construction consultants Robinson Low Francis LLP.
  • Better HoldCo Inc., a US-based digital homeownership platform, in its acquisition of the UK-based digital mortgage and insurance broker Trussle.
  • AstraZeneca, in agreements with governmental authorities for the distribution of the University of Oxford's COVID-19 vaccine.
  • Pfizer, in agreements for the supply to various governmental authorities of Pfizer and BioNTech’s mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2.
  • Steering committee of term loan lenders owed in excess of $2 billion with respect to the issuance of a new $450 million term loan facility to Cineworld Group Plc (Cineworld), a publicly listed company on the London Stock Exchange and the world's second-largest cinema chain.


A Beginner’s Guide to Life Sciences M&A Deals
Arnold & Porter Webinar


  • American Law and Politics, University of Southern California, 2016
  • MA, Law, Queens' College Cambridge, 2015
  • England and Wales

Email Disclaimer